In hatchery mass application, allantoic fluid harvests from specific-pathogen-free embryonated chicken eggs containing live attenuated infectious bronchitis virus are depth-filtered, blended with a sucrose–gelatin lyoprotectant, and lyophilised before transport to the vaccination cabinet. The reconstituted suspension is sprayed through nozzles producing a droplet band of 100–150 µm, with nozzle pressure held at 2.0–3.0 bar to limit shear damage to the enveloped virion while still achieving uniform flock exposure. The formulation addition ratio is adjusted to deliver 10^3.0–10^4.5 EID50 per 0.03 mL dose equivalent, and the liquid volume is calibrated to 100–400 mL per 1,000 chicks so that ocular and upper respiratory mucosa receive consistent coverage without excessive coalescence on down feathers. Compliance for the live IBV bulk antigen and the finished reconstituted solution falls under Ph. Eur. monograph 0442, 9 CFR 113.327, and OIE Terrestrial Manual Chapter 3.3.2; sterility is confirmed by Ph. Eur. 2.6.1, and freedom from mycoplasma is verified by Ph. Eur. 2.6.7. Downstream production involves allantoic sac inoculation of 9–11-day embryonated SPF eggs, harvest at 36–48 h post inoculation, clarification through 0.8/0.45 µm depth filtration, blending with sterilised lyoprotectant at 40–60% v/v of the final aqueous phase, and freeze-drying in 10 mL Type I glass vials to residual moisture below 2.5%. Terminal finished product types are multi-dose freeze-dried cakes in 500-dose and 1,000-dose vials supplied with separate sterile diluent, reconstituted in the hatchery immediately before coarse-spray administration. Chlorinated diluents and unrinsed metal containers are avoided because residual oxidising agents and heavy-metal ions reduce viral titre within minutes.

Why Is Chlorine Neutralization Required Before Drinking-Water IBV Vaccination?

Before the API is introduced into farm water, residual chlorine and chloramine species must be chemically reduced because free live IBV loses infectivity within seconds in their presence. The soluble powder or effervescent tablet presentation is added at a ratio of 1 dose per bird into the volume of water consumed over 1.5–2.0 h, typically 10–20 mL per bird for broilers, while sodium thiosulfate is metered at 15 mg/L and skim milk powder at 2.5 g/L to neutralise residual oxidants and provide proteinaceous thermal protection. Water pH is held between 6.8 and 7.2, and water temperature is maintained at 15–20°C to avoid heat-associated titre loss during the drinking period. Compliance for this presentation is governed by Ph. Eur. 0442 for live avian infectious bronchitis vaccine, 9 CFR 113.327, and OIE Terrestrial Manual 3.3.2, with release titration performed as EID50 in 9–11-day embryonated SPF eggs and extraneous-agent testing per Ph. Eur. 2.6.7. Downstream production includes low-shear blending of stabilised antigen with lactose or sorbitol carriers, filling into aluminium-foil sachets, or compression into effervescent tablets with hardness 50–70 N; the effervescent couple comprises citric acid 15% w/w and sodium bicarbonate 20% w/w, giving disintegration in cool water under 3 min when tested by Ph. Eur. 2.9.1. Terminal finished product types are water-dispersible powder sachets and effervescent tablets in 1,000-dose and 5,000-dose pack sizes, administered through a calibrated proportioner at 1:100 or 1:200 after all chlorine and disinfectant residues have been removed from the line.

Oil-Emulsion Inactivated IBV Antigen for Parenteral Booster Programs

Breeder and layer immunity programs rely on inactivated IBV antigen formulated in a water-in-oil emulsion to generate systemic antibody after live priming. The aqueous antigen phase typically constitutes 20–30% w/w of the final emulsion, while the oil phase, inclusive of 5–8% w/w sorbitan monooleate emulsifier, makes up 70–80% w/w; each 0.5 mL intramuscular or subcutaneous dose contains antigen equivalent to a pre-inactivation titre of 10^7.0–10^8.0 EID50 per bird. Compliance is anchored to Ph. Eur. monograph 0443 for inactivated avian infectious bronchitis vaccine, 9 CFR 113.328, and OIE Terrestrial Manual Chapter 3.3.2, with potency demonstrated by serological response in target birds and finished sterility verified by Ph. Eur. 2.6.1; residual inactivating agent is controlled to 0.1% formalin equivalent or 10 mM BEI after neutralisation. Downstream processing begins with allantoic fluid clarification, followed by antigen concentration through tangential-flow ultrafiltration with 100 kDa nominal molecular weight cut-off cassettes, inactivation with 0.1% v/v formalin at 37°C for 24 h or binary ethylenimine at 10 mM for 16 h, and emulsification in a rotor-stator high-shear mixer at 10,000 rpm for 15 min to achieve a dispersed-phase droplet size D90 below 1.0 µm. Terminal finished product types are inactivated oil-emulsion vaccines in 500 mL and 1,000 mL HDPE or PET multi-dose vials, frequently combined with Newcastle disease, egg drop syndrome, or reovirus antigens to reduce injection frequency. The emulsion must not be frozen, and vials require gentle shaking before administration to restore uniform viscosity after cold storage at 2–8°C.

When the API Is Lyophilized for Oculo-Nasal Individual Dose Administration

When individual bird coverage and controlled dose accuracy are required, the live-attenuated IBV API is lyophilised with a sucrose–gelatin matrix and reconstituted for eye-drop or nasal-drop administration. The lyoprotectant formulation includes sucrose at 2.0–5.0% w/v, gelatin at 1.0–2.0% w/v, and potassium phosphate buffer at 0.01–0.05 M pH 7.2; the final reconstituted dose of 0.03 mL per bird is targeted to deliver 10^3.5–10^4.5 EID50. Residual moisture after lyophilisation is controlled below 2.0% by Karl Fischer titration per Ph. Eur. 2.5.32, and reconstitution time is specified as under 60 s with sterile diluent at 20–25°C. Compliance for this presentation follows Ph. Eur. 0442, 9 CFR 113.327, and EU GMP Annex 2 for biological medicinal products, with virus titre stability monitored at 2–8°C through the assigned shelf-life. Downstream production uses 9–11-day embryonated SPF chicken eggs for virus propagation, cold-chain allantoic fluid harvest, depth filtration, aseptic blending with sterilised lyoprotectant, and freeze-drying in a cycle that freezes the filled vials at -40°C, performs primary drying at -20°C under 50–100 µbar chamber pressure, and completes secondary drying at 20°C for 6–10 h. Terminal finished product types are single-dose packs or multi-dose 100-dose and 1,000-dose vials with matching diluent, used within 4 h of reconstitution and never refrozen.

Effervescent tablet presentation of live-attenuated IBV API is produced by direct compression of a stabilised lyophilised powder premix, enabling rapid dispersion in farm water without manual rehydration of freeze-dried cake. The addition ratio in the compressed core is adjusted to 20–40% w/w API-containing stabilised powder, with citric acid at 15% w/w, sodium bicarbonate at 20% w/w, and polyethylene glycol 6000 at 1.0–2.0% w/w as anti-caking binder; one 1,000-dose tablet is formulated to disperse in 5 L of water as a stock solution for subsequent dilution through a proportioner. Tablet hardness is maintained at 50–70 N, friability below 1.0%, and disintegration time below 3 min in water at 15°C when tested by Ph. Eur. 2.9.1. Compliance for the tablet format remains under Ph. Eur. 0442 for live IBV vaccine, 9 CFR 113.327, and OIE Terrestrial Manual 3.3.2; release testing includes virus titration in embryonated eggs and residual moisture testing by Ph. Eur. 2.5.32. Downstream production includes dry blending in a V-blender at 15 rpm for 20 min, compression on a rotary tablet press at 10–12 kN compaction force, aluminium-foil strip packaging with desiccant encapsulation, and cold-chain storage at 2–8°C. Terminal finished product types are effervescent tablets in strip packs of 10 tablets per carton, with each tablet delivering 1,000 or 5,000 doses for drinking-water vaccination in broiler flocks. Because national registrations for effervescent IBV tablet presentations are not uniform across regulatory jurisdictions, local licensing and import requirements require verification before field distribution.

Granulated Water-Soluble Premix in Nipple Drinker Distribution Lines

For poultry farms with nipple drinker systems, granulated water-soluble premix variants are manufactured to reduce dust formation and caking that cause uneven vaccine dosing from fine-powder sachets. The API is incorporated at 10–25% w/w onto a water-soluble carrier composed of lactose monohydrate and sorbitol, with polyvinylpyrrolidone K30 binder at 2.0–4.0% w/w and a pH-modifying citric acid/sodium bicarbonate pair at 15% w/w and 20% w/w respectively. The resulting granule is sieved to 200–800 µm, dissolves within 3 min in cool water at 15–20°C, and delivers one dose per bird when the labelled sachet mass for the flock size is added to the volume of water consumed over 1.5–2.0 h. Compliance for granulated live-attenuated IBV formulations is referenced to Ph. Eur. 0442, 9 CFR 113.327, and OIE Terrestrial Manual 3.3.2; batch release requires virus titration in embryonated eggs and moisture content below 1.5% by Ph. Eur. 2.5.32. Downstream production uses a fluidised bed granulator with inlet air at 40°C and exhaust humidity controlled to avoid antigen inactivation, binder sprayed through a top-spray nozzle at 0.5–1.0 bar atomising pressure, and final drying until residual moisture is below 1.5%; the dried granules are then filled into laminated aluminium sachets to maintain viability. Terminal finished product types are water-soluble granules in 1,000-dose, 5,000-dose, and 10,000-dose sachets, intended for stock-solution preparation and continuous distribution through nipple drinker lines without central-tank premixing. Granules are moisture-sensitive, and prolonged dissolution in water above 25°C must be avoided to prevent titre loss before consumption.